Last update Aug. 6, 2022

Atracurium Besilate, Atracurium Besylate

Compatible

Safe substance and/or breastfeeding is the best option.

It is a non-depolarizing muscle relaxant drug with a peripheral action that is used as premedication for endotracheal intubation, general anesthesia and mechanical ventilation. Intravenous administración

Since the last update we have not found published data on its excretion in breastmilk.

Its moderately elevated molecular weight and rapid half-life elimination period (about 20 minutes) make it highly unlikely that significant quantities will pass into breast milk. (Dalal 2014, Spigset 1994)

Also, quaternary ammonium muscle relaxants are poorly absorbed from the gastro-intestinal tract; its low oral bioavailability renders the pass of this agent to the infant's plasma highly unlikely. (Spigset 1994)

Atracurium does not prevent a mother from breast feeding her baby shortly after recovering from anesthesia if she is awake and in good condition.

Experts authors consider the use of this medication to be probably compatible during breastfeeding. (Briggs 2015, Dalal 2014)

Alternatives

We do not have alternatives for Atracurium Besilate, Atracurium Besylate since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Atracurium Besilate, Atracurium Besylate in other languages or writings:

Group

Atracurium Besilate, Atracurium Besylate belongs to this group or family:

Tradenames

Main tradenames from several countries containing Atracurium Besilate, Atracurium Besylate in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. ≈ 0 %
Molecular weight 1.244 daltons
Protein Binding 82 %
VD 0.16 l/Kg
Tmax 0.1 hours
T½ 0.3 hours

References

  1. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer Health. Tenth edition (acces on line) 2015
  2. Dalal PG, Bosak J, Berlin C. Safety of the breast-feeding infant after maternal anesthesia. Paediatr Anaesth. 2014 Abstract
  3. Atracurio. Ficha técnica. 2011 Full text (in our servers)
  4. Ferriols Lisart R,Ferriols Lisart F. Farmacología clínica y usos terapéuticos del Mivacurio. Farm Hosp. 1997 Full text (in our servers)
  5. Atracurium. Drug Summary. 1996 Full text (in our servers)
  6. Spigset O. Anaesthetic agents and excretion in breast milk. Acta Anaesthesiol Scand. 1994 Abstract
  7. Colin JN, Singlas E. [Metabolism and pharmacokinetics of atracurium]. Ann Fr Anesth Reanim. 1985 Abstract
  8. Ward S, Neill EA, Weatherley BC, Corall IM. Pharmacokinetics of atracurium besylate in healthy patients (after a single i.v. bolus dose). Br J Anaesth. 1983 Abstract

Total visits

16,878

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM